Moderna Suing Pfizer For COVID-19 Vaccine Patent Infringement

REUTERS/Dado Ruvic/Illustration

Daily Caller News Foundation logo
Trevor Schakohl Legal Reporter
Font Size:

Moderna is filing patent infringement lawsuits against Pfizer and BioNTech in U.S. district court and German regional court Friday in connection with the two companies’ COVID-19 vaccine, Moderna announced.

Moderna alleges Pfizer and BioNTech’s Comirnaty vaccine breaches its mRNA technology patents submitted between 2010 and 2016. It claims they developed their vaccine by copying the technology Moderna used to make its mRNA COVID-19 vaccine, Spikevax.

“We are filing these lawsuits to protect the innovative mRNA technology platform that we pioneered, invested billions of dollars in creating, and patented during the decade preceding the COVID-19 pandemic,” Moderna CEO Stéphane Bancel said. “This foundational platform, which we began building in 2010, along with our patented work on coronaviruses in 2015 and 2016, enabled us to produce a safe and highly effective COVID-19 vaccine in record time after the pandemic struck.” (RELATED: Legendary Athlete Calls Biden Vaccine Policy ‘A Joke’, Stands Up For Novak Djokovic)

Moderna insisted it is not trying to remove Comirnaty from the market or win damages for actions taken before March 8, 2022. The company said it recognized “the need to ensure continued access to these lifesaving vaccines.”

In a statement, Pfizer told the Daily Caller News Foundation it has “not yet fully reviewed the complaint” but is “surprised by the litigation.”

“We remain confident in our intellectual property supporting the Pfizer/BioNTech vaccine and will vigorously defend against the allegations of the lawsuit,” it said.

BioNTech directed the DCNF to an online statement saying it will “vigorously defend against all allegations of patent infringement.”

This story has been updated with comment from Pfizer and BioNTech.

All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact